Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection
David J. DiLillo, … , Patrick C. Wilson, Jeffrey V. Ravetch
David J. DiLillo, … , Patrick C. Wilson, Jeffrey V. Ravetch
Published January 5, 2016
Citation Information: J Clin Invest. 2016;126(2):605-610. https://doi.org/10.1172/JCI84428.
View: Text | PDF
Concise Communication Immunology Article has an altmetric score of 8

Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection

  • Text
  • PDF
Abstract

In vivo protection by antimicrobial neutralizing Abs can require the contribution of effector functions mediated by Fc-Fcγ receptor (Fc-FcγR) interactions for optimal efficacy. In influenza, broadly neutralizing anti-hemagglutinin (anti-HA) stalk mAbs require Fc-FcγR interactions to mediate in vivo protection, but strain-specific anti-HA head mAbs do not. Whether this rule applies only to anti-stalk Abs or is applicable to any broadly neutralizing Ab (bNAb) against influenza is unknown. Here, we characterized the contribution of Fc-FcγR interactions during in vivo protection for a panel of 13 anti-HA mAbs, including bNAbs and non-neutralizing Abs, against both the stalk and head domains. All classes of broadly binding anti-HA mAbs required Fc-FcγR interactions to provide protection in vivo, including those mAbs that bind the HA head and those that do not neutralize virus in vitro. Further, a broadly neutralizing anti-neuraminidase (anti-NA) mAb also required FcγRs to provide protection in vivo, but a strain-specific anti-NA mAb did not. Thus, these findings suggest that the breadth of reactivity of anti-influenza Abs, regardless of their epitope, necessitates interactions with FcγRs on effector cell populations to mediate in vivo protection. These findings will guide the design of antiviral Ab therapeutics and inform vaccine design to elicit Abs with optimal binding properties and effector functions.

Authors

David J. DiLillo, Peter Palese, Patrick C. Wilson, Jeffrey V. Ravetch

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 Total
Citations: 8 29 28 26 49 30 40 36 35 16 297
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (297)

Title and authors Publication Year
Administration of antigenically distinct influenza viral particle combinations as an influenza vaccine strategy
Zhu X, Luo Z, Leonard RA, Hamele CE, Spreng RL, Heaton NS
PLOS Pathogens 2025
Antiviral strategies against influenza virus: an update on approved and innovative therapeutic approaches
Bonomini A, Mercorelli B, Loregian A
Cellular and Molecular Life Sciences: CMLS 2025
A statistical framework for quantifying the nuclear export rate of influenza viral mRNAs
Miura M, Kiuchi N, Lau SY, Mok BW, Ushirogawa H, Naito T, Chen H, Saito M
eLife 2025
Cross-Reactive Fc-Mediated Antibody Responses to Influenza HA Stem Region in Human Sera Following Seasonal Vaccination
Nishiyama A, Nogimori T, Masuta Y, Matsuura T, Kase T, Kondo K, Ohfuji S, Nakagama Y, Kaku N, Nakagama S, Nitahara Y, Takahashi Y, Kakeya H, Kido Y, Fukushima W, Yamamoto T
Vaccines 2025
Conserved sites on the influenza H1 and H3 hemagglutinin recognized by human antibodies
Maurer DP, Vu M, Ferreira Ramos AS, Dugan HL, Khalife P, Geoghegan JC, Walker LM, Bajic G, Schmidt AG
Science Advances 2025
A monoclonal anti-hemagglutinin stem antibody modified with zanamivir protects against both influenza A and B viruses
Liu X, Balligand T, Le Gall C, Ploegh HL
Proceedings of the National Academy of Sciences of the United States of America 2025
Immune history shapes human antibody responses to H5N1 influenza viruses.
Garretson TA, Liu J, Li SH, Scher G, Santos JJS, Hogan G, Vieira MC, Furey C, Atkinson RK, Ye N, Ort JT, Kim K, Hernandez KA, Eilola T, Schultz DC, Cherry S, Cobey S, Hensley SE
Nature medicine 2025
Kinetic MUNANA assay reveals functionally relevant antibody epitopes on Influenza A virus neuraminidase.
Smirnov IV, Besavilla DF, Schön K, Axelsson H, Angeletti D
Npj viruses 2025
Multivalent next generation influenza virus vaccines protect against seasonal and pre-pandemic viruses.
Uno N, Ross TM
Scientific Reports 2024
High-resolution map of the Fc functions mediated by COVID-19-neutralizing antibodies
Paciello I, Maccari G, Pantano E, Andreano E, Rappuoli R
Proceedings of the National Academy of Sciences 2024
Applying valency-based immuno-selection to generate broadly cross-reactive antibodies against influenza hemagglutinins.
Hinke DM, Anderson AM, Katta K, Laursen MF, Tesfaye DY, Werninghaus IC, Angeletti D, Grødeland G, Bogen B, Braathen R
Nature Communications 2024
Prefusion-stabilized SARS-CoV-2 S2-only antigen provides protection against SARS-CoV-2 challenge
Hsieh CL, Leist SR, Miller EH, Zhou L, Powers JM, Tse AL, Wang A, West A, Zweigart MR, Schisler JC, Jangra RK, Chandran K, Baric RS, McLellan JS
Nature Communications 2024
Immunogenicity of chimeric hemagglutinins delivered by an orf virus vector platform against swine influenza virus
do Nascimento GM, de Oliveira PS, Butt SL, Diel DG
Frontiers in immunology 2024
Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination
Clark J, Hoxie I, Adelsberg DC, Sapse IA, Andreata-Santos R, Yong JS, Amanat F, Tcheou J, Raskin A, Singh G, González-Domínguez I, Edgar JE, Bournazos S, Sun W, Carreño JM, Simon V, Ellebedy AH, Bajic G, Krammer F
2024
Characterization of antibody-dependent cellular phagocytosis in patients infected with hepatitis C virus with different clinical outcomes.
Adhikari A, Abayasingam A, Brasher NA, Kim HN, Lord M, Agapiou D, Maher L, Rodrigo C, Lloyd AR, Bull RA, Tedla N
Journal of Medical Virology 2024
A Dual-domain Engineered Antibody for Efficient HBV Suppression and Immune Responses Restoration.
Jiang Y, Chen X, Ye X, Wen C, Xu T, Yu C, Ning W, Wang G, Xiang X, Liu X, Wang Y, Chen Y, Liu X, Shi C, Liu C, Yuan Q, Chen Y, Zhang T, Luo W, Xia N
2024
Broadly Reactive Nanobody Targeting the H3 Hemagglutinin of the Influenza A Virus.
Shcheblyakov DV, Voronina DV, Favorskaya IA, Esmagambetov IB, Alekseeva IA, Korobkova AI, Ryabova EI, Derkaev AA, Kan VY, Dzharullaeva AS, Tukhvatulin AI, Bandelyuk AS, Shmarov MM, Logunov DY, Gintsburg AL
Acta Naturae 2024
Eliciting a single amino acid change by vaccination generates antibody protection against group 1 and group 2 influenza A viruses
Ray R, Mohamed FA, Maurer DP, Huang J, Alpay BA, Ronsard L, Xie Z, Han J, Fernandez-Quintero M, Phan QA, Ursin RL, Vu M, Kirsch KH, Prum T, Rosado VC, Bracamonte-Moreno T, Okonkwo V, Bals J, McCarthy C, Nair U, Kanekiyo M, Ward A, Schmidt AG, Batista FD, Lingwood D
Immunity 2024
A chimeric haemagglutinin-based universal influenza virus vaccine boosts human cellular immune responses directed towards the conserved haemagglutinin stalk domain and the viral nucleoprotein
Bliss CM, Nachbagauer R, Mariottini C, Cuevas F, Feser J, Naficy A, Bernstein DI, Guptill J, Walter EB, Berlanda-Scorza F, Innis BL, García-Sastre A, Palese P, Krammer F, Coughlan L
EBioMedicine 2024
Nanoparticle display of neuraminidase elicits enhanced antibody responses and protection against influenza A virus challenge
Pascha MN, Ballegeer M, Roelofs MC, Meuris L, Albulescu IC, van Kuppeveld FJ, Hurdiss DL, Bosch BJ, Zeev-Ben-Mordehai T, Saelens X, de Haan CA
npj Vaccines 2024
Capsid virus-like particle display improves recombinant influenza neuraminidase antigen stability and immunogenicity in mice
Kang H, Martinez MR, Aves KL, Okholm AK, Wan H, Chabot S, Malik T, Sander AF, Daniels R
iScience 2024
Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions
Pierre CN, Adams LE, Higgins JS, Anasti K, Goodman D, Mielke D, Stanfield-Oakley S, Powers JM, Li D, Rountree W, Wang Y, Edwards RJ, Alam SM, Ferrari G, Tomaras GD, Haynes BF, Baric RS, Saunders KO
PLoS pathogens 2024
A broadly neutralizing human monoclonal antibody generated from transgenic mice immunized with HCMV particles limits virus infection and proliferation
Atanasoff KE, Parsons AJ, Ophir SI, Lurain N, Kraus T, Moran T, Duty JA, Tortorella D
Journal of virology 2024
Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine
Casazza JP, Hofstetter AR, Costner PJ, Holman LA, Hendel CS, Widge AT, Wu RL, Whalen WR, Cunningham J, Arthur A, Wang X, Ola A, Saunders J, Mendoza F, Novik L, Burgos Florez MC, Ortega-Villa AM, Apte PJ, Strom L, Wang L, Imam M, Basappa M, Naisan M, Castro M, Trost JF, Narpala SR, Vanderven HA, Yamshchikov GV, Berkowitz NM, Gordon IJ, Plummer SH, Wycuff DL, Vazquez S, Gillespie RA, Creanga A, Adams WC, Carlton K, Gall JG, McDermott AB, Serebryannyy LA, Houser KV, Koup RA, Graham BS, Ledgerwood JE, Mascola JR, Pierson TC, Andrews SF, Kanekiyo M, Dropulic LK
NPJ Vaccines 2024
A comprehensive review of influenza B virus, its biological and clinical aspects
Ashraf MA, Raza MA, Amjad MN, ud Din G, Yue L, Shen B, Chen L, Dong W, Xu H, Hu Y
Frontiers in Microbiology 2024
Intranasal administration of octavalent next-generation influenza vaccine elicits protective immune responses against seasonal and pre-pandemic viruses
Uno N, Ebensen T, Guzman CA, Ross TM
Journal of Virology 2024
The lipid globotriaosylceramide promotes germinal center B cell responses and antiviral immunity
Sharma P, Zhang X, Ly K, Zhang Y, Hu Y, Yongxin Ye A, Hu J, Kim JH, Lou M, Wang C, Celuzza Q, Kondo Y, Furukawa K, Bundle DR, Furukawa K, Alt FW, Winau F
Science (New York, N.Y.) 2024
Isolation of human antibodies against influenza B neuraminidase and mechanisms of protection at the airway interface
Wolters RM, Ferguson J, Nuñez IA, Chen EE, Sornberger T, Myers L, Oeverdieck S, Raghavan SS, Kona C, Handal LS, Esilu TE, Davidson E, Doranz BJ, Engdahl TB, Kose N, Williamson LE, Creech CB, Gibson-Corley KN, Ward AB, Crowe JE Jr
Immunity 2024
Improved influenza vaccine responses after expression of multiple viral glycoproteins from a single mRNA.
Leonard RA, Burke KN, Spreng RL, Macintyre AN, Tam Y, Alameh MG, Weissman D, Heaton NS
Nature communications 2024
Immune history shapes human antibody responses to H5N1 influenza viruses
Garretson TA, Liu J, Li SH, Scher G, Santos JJ, Hogan G, Vieira MC, Furey C, Atkinson RK, Ye N, Ort J, Kim K, Hernandez KA, Eilola T, Schultz DC, Cherry S, Cobey S, Hensley SE
medRxiv 2024
A multi-antigen vaccinia vaccine broadly protected mice against SARS-CoV-2 and influenza A virus while also targeting SARS-CoV-1 and MERS-CoV
Gao N, Yang T, Dong L, Tang W, Cao K, Ding L, Zhu C, Bai S, Xia A, Zhu Y, Zhao C, Peng H, Xu J, Zhang X
Frontiers in Immunology 2024
Fc‐FcγR interactions during infections: From neutralizing antibodies to antibody‐dependent enhancement
Edgar JE, Bournazos S
Immunological Reviews 2024
Induction of Fc-dependent functional antibodies against different variants of SARS-CoV-2 varies by vaccine type and prior infection
Harris AW, Kurtovic L, Nogueira J, Bouzas I, Opi DH, Wines BD, Lee WS, Hogarth PM, Poumbourios P, Drummer HE, Valim C, Porto LC, Beeson JG
Communications Medicine 2024
Antibody-mediated control mechanisms of viral infections
Mackin SR, Sariol A, Diamond MS
Immunological reviews 2024
Transforming Vaccinology
Rappuoli R, Alter G, Pulendran B
Cell 2024
Sialylated IgG induces the transcription factor REST in alveolar macrophage to protect against lung inflammation and severe influenza disease
Chakraborty S, Cheng BY, Edwards DL, Gonzalez JC, Chiu DK, Zheng H, Scallan C, Guo X, Tan GS, Coffey GP, Conley PB, Hume PS, Janssen WJ, Byers DE, Mudd PA, Taubenberger J, Memoli M, Davis MM, Chua KF, Diamond MS, Andreakos E, Khatri P, Wang TT
Immunity 2024
Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination
Clark JJ, Hoxie I, Adelsberg DC, Sapse IA, Andreata-Santos R, Yong JS, Amanat F, Tcheou J, Raskin A, Singh G, González-Domínguez I, Edgar JE, Bournazos S, Sun W, Carreño JM, Simon V, Ellebedy AH, Bajic G, Krammer F
Cell reports 2024
Understanding the treatment benefit of hyperimmune anti-influenza intravenous immunoglobulin (Flu-IVIG) for severe human influenza
Hillary Vanderven, Deborah Wentworth, Win Min Han, Heidi Peck, Ian Barr, Richard Davey, John Beigel, Dominic Dwyer, Mamta K. Jain, Brian Angus, Christian Brandt, Analia Mykietiuk, Matthew Law, Jim Neaton, Stephen Kent
JCI Insight 2023
Enhancing the protection of influenza virus vaccines with BECC TLR4 adjuvant in aged mice.
Haupt R, Baracco L, Harberts EM, Loganathan M, Kerstetter LJ, Krammer F, Coughlan L, Ernst RK, Frieman MB
Scientific Reports 2023
Systems serology-based comparison of antibody effector functions induced by adjuvanted vaccines to guide vaccine design.
Loos C, Coccia M, Didierlaurent AM, Essaghir A, Fallon JK, Lauffenburger D, Luedemann C, Michell A, van der Most R, Zhu AL, Alter G, Burny W
npj Vaccines 2023
ADCC: An underappreciated correlate of cross-protection against influenza?
de Vries RD, Hoschler K, Rimmelzwaan GF
Frontiers in immunology 2023
IgG1 Is the Optimal Subtype for Treating Atherosclerosis by Inducing M2 Macrophage Differentiation, and Is Independent of the FcγRIIA Gene Polymorphism.
Duan R, Liu Y, Tang D, Lin R, Huang J, Zhao M
International journal of molecular sciences 2023
Bivalent vaccines effectively protect mice against influenza A and respiratory syncytial viruses
Raman SN, Zetner A, Hashem AM, Patel D, Wu J, Gravel C, Gao J, Zhang W, Pfeifle A, Tamming L, Parikh K, Cao J, Tam R, Safronetz D, Chen W, Johnston MJ, Wang L, Sauve S, Rosu-Myles M, Domselaar GV, Li X
Emerging Microbes & Infections 2023
Enhancing the therapeutic activity of hyperimmune IgG against chikungunya virus using FcγRIIIa affinity chromatography
Fox JM, Roy V, Gunn BM, Bolton GR, Fremont DH, Alter G, Diamond MS, Boesch AW
Frontiers in immunology 2023
Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies
Struble EB, Rawson JM, Stantchev T, Scott D, Shapiro MA
Pharmaceutics 2023
A pan-influenza antibody inhibiting neuraminidase via receptor mimicry.
Momont C, Dang HV, Zatta F, Hauser K, Wang C, di Iulio J, Minola A, Czudnochowski N, De Marco A, Branch K, Donermeyer D, Vyas S, Chen A, Ferri E, Guarino B, Powell AE, Spreafico R, Yim SS, Balce DR, Bartha I, Meury M, Croll TI, Belnap DM, Schmid MA, Schaiff WT, Miller JL, Cameroni E, Telenti A, Virgin HW, Rosen LE, Purcell LA, Lanzavecchia A, Snell G, Corti D, Pizzuto MS
Nature 2023
Fc-Effector-Independent in vivo Activity of a Potent Influenza B Neuraminidase Broadly Neutralizing Antibody
Khalil AM, Piepenbrink MS, Markham I, Basu M, Martinez-Sobrido L, Kobie JJ
Viruses 2023
An armed anti-immunoglobulin light chain nanobody protects mice against influenza A and B infections
Liu X, Balligand T, Carpenet C, Ploegh HL
Science Immunology 2023
Neuraminidase delivered as an APC-targeted DNA vaccine induces protective antibodies against influenza
Werninghaus IC, Hinke DM, Fossum E, Bogen B, Braathen R
Molecular Therapy 2023
Single-dose mucosal replicon-particle vaccine protects against lethal Nipah virus infection up to 3 days after vaccination.
Welch SR, Spengler JR, Genzer SC, Coleman-McCray JD, Harmon JR, Sorvillo TE, Scholte FEM, Rodriguez SE, O'Neal TJ, Ritter JM, Ficarra G, Davies KA, Kainulainen MH, Karaaslan E, Bergeron É, Goldsmith CS, Lo MK, Nichol ST, Montgomery JM, Spiropoulou CF
Science Advances 2023
Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions
Pierre CN, Adams LE, Anasti K, Goodman D, Stanfield-Oakley S, Powers JM, Li D, Rountree W, Wang Y, Edwards RJ, Munir Alam S, Ferrari G, Tomaras GD, Haynes BF, Baric RS, Saunders KO
2023
Polyfunctional antibodies: a path towards precision vaccines for vulnerable populations
Purcell RA, Theisen RM, Arnold KB, Chung AW, Selva KJ
Frontiers in immunology 2023
Antibody-mediated NK cell activation as a correlate of immunity against influenza infection.
Boudreau CM, Burke JS 4th, Yousif AS, Sangesland M, Jastrzebski S, Verschoor C, Kuchel G, Lingwood D, Kleanthous H, De Bruijn I, Landolfi V, Sridhar S, Alter G
Nature Communications 2023
Designed nanoparticles elicit cross-reactive antibody responses to conserved influenza virus hemagglutinin stem epitopes
McCraw DM, Myers ML, Gulati NM, Prabhakaran M, Brand J, Andrews S, Gallagher JR, Maldonado-Puga S, Kim AJ, Torian U, Syeda H, Boyoglu-Barnum S, Kanekiyo M, McDermott AB, Harris AK
PLoS pathogens 2023
Vaccine-induced neutralizing antibody responses to seasonal influenza virus H1N1 strains are not enhanced during subsequent pandemic H1N1 infection
Mooij P, Mortier D, Aartse A, Murad AB, Correia R, Roldão A, Alves PM, Fagrouch Z, Eggink D, Stockhofe N, Engelhardt OG, Verschoor EJ, van Gils MJ, Bogers WM, Carrondo MJ, Remarque EJ, Koopman G
Frontiers in immunology 2023
Protective mechanisms of nonneutralizing antiviral antibodies
Chandler TL, Yang A, Otero CE, Permar SR, Caddy SL
PLoS pathogens 2023
Human anti-N1 monoclonal antibodies elicited by pandemic H1N1 virus infection broadly inhibit HxN1 viruses in vitro and in vivo
Hansen L, McMahon M, Turner HL, Zhu X, Turner JS, Ozorowski G, Stadlbauer D, Vahokoski J, Schmitz AJ, Rizk AA, Alsoussi WB, Strohmeier S, Yu W, Choreño-Parra JA, Jiménez-Alvarez L, Cruz-Lagunas A, Zúñiga J, Mudd PA, Cox RJ, Wilson IA, Ward AB, Ellebedy AH, Krammer F
Immunity 2023
Antibodies elicited in humans upon chimeric hemagglutinin-based influenza virus vaccination confer FcγR-dependent protection in vivo
Edgar JE, Trezise S, Anthony RM, Krammer F, Palese P, Ravetch JV, Bournazos S
Proceedings of the National Academy of Sciences 2023
Characterization of non-neutralizing human monoclonal antibodies that target the M1 and NP of influenza A viruses
Rijnink WF, Stadlbauer D, Puente-Massaguer E, Okba NM, Kirkpatrick Roubidoux E, Strohmeier S, Mudd PA, Schmitz A, Ellebedy A, McMahon M, Krammer F
Journal of virology 2023
Fc-mediated functions and the treatment of severe respiratory viral infections with passive immunotherapy - a balancing act.
Vanderven HA, Kent SJ
Frontiers in immunology 2023
Difference in respiratory syncytial virus-specific Fc-mediated antibody effector functions between children and adults.
Lakerveld AJ, Gelderloos AT, Schepp RM, de Haan CAM, van Binnendijk RS, Rots NY, van Beek J, van Els CACM, van Kasteren PB
Clinical & Experimental Immunology 2023
From bench to bedside via bytes: Multi-omic immunoprofiling and integration using machine learning and network approaches.
Xiao H, Rosen A, Chhibbar P, Moise L, Das J
Human Vaccines & Immunotherapeutics 2023
Development of Self-Assembled Protein Nanocage Spatially Functionalized with HA Stalk as a Broadly Cross-Reactive Influenza Vaccine Platform.
Park J, Champion JA
ACS Nano 2023
Protective human antibodies against a conserved epitope in pre- and postfusion influenza hemagglutinin
Finney J, Moseman AP, Kong S, Watanabe A, Song S, Walsh RM Jr, Kuraoka M, Kotaki R, Moseman EA, McCarthy KR, Liao D, Liang X, Nie X, Lavidor O, Abbott R, Harrison SC, Kelsoe G
Proceedings of the National Academy of Sciences 2023
Protective efficacy of a universal influenza mRNA vaccine against the challenge of H1 and H5 influenza A viruses in mice.
Li Y, Wang X, Zeng X, Ren W, Liao P, Zhu B
2023
Adenovirus-based vaccines—a platform for pandemic preparedness against emerging viral pathogens
L Coughlan, E Kremer, D Shayakhmetov
Molecular Therapy 2022
A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice
C Bliss, A Freyn, T Caniels, V Leyva-Grado, R Nachbagauer, W Sun, G Tan, V Gillespie, M McMahon, F Krammer, A Hill, P Palese, L Coughlan
Molecular Therapy 2022
Antibodies directed towards neuraminidase restrict influenza virus replication in primary human bronchial epithelial cells
A Smet, J Catani, T Ysenbaert, A Gonçalves, H Kleanthous, T Vogel, X Saelens, E Job, S Herfst
PloS one 2022
Mucosal immune responses to infection and vaccination in the respiratory tract
R Mettelman, E Allen, P Thomas
Immunity 2022
Fc-Mediated Functions of Porcine IgG Subclasses
Paudyal B, Mwangi W, Rijal P, Schwartz JC, Noble A, Shaw A, Sealy JE, Bonnet-Di Placido M, Graham SP, Townsend A, Hammond JA, Tchilian E
Frontiers in immunology 2022
Functional antibody-dependent cell mediated cytotoxicity (ADCC) responses to vaccine and circulating influenza strains following vaccination.
Chen X, Sun HY, Lee CY, Rostad CA, Trost J, Abreu RB, Carlock MA, Wilson JR, Gansebom S, Ross TM, Steinhauer DA, Anderson EJ, Anderson LJ
Virology 2022
Targeting Xcr1 on Dendritic Cells Rapidly Induce Th1-Associated Immune Responses That Contribute to Protection Against Influenza Infection
Tesfaye DY, Bobic S, Lysén A, Huszthy PC, Gudjonsson A, Braathen R, Bogen B, Fossum E
Frontiers in immunology 2022
Evaluation of strategies to modify Anti-SARS-CoV-2 monoclonal antibodies for optimal functionality as therapeutics
House RV, Broge TA, Suscovich TJ, Snow DM, Tomic MT, Nonet G, Bajwa K, Zhu G, Martinez Z, Hackett K, Earnhart CG, Dorsey NM, Hopkins SA, Natour DS, Davis HD, Anderson MS, Gainey MR, Cobb RR
PloS one 2022
Omicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines.
Bartsch YC, Tong X, Kang J, Avendaño MJ, Serrano EF, García-Salum T, Pardo-Roa C, Riquelme A, Cai Y, Renzi I, Stewart-Jones G, Chen B, Medina RA, Alter G
Science Translational Medicine 2022
Dissecting Fc signatures of protection in neonates following maternal influenza vaccination in a placebo-controlled trial
Boudreau CM, Burke JS IV, Shuey KD, Wolf C, Katz J, Tielsch J, Khatry S, LeClerq SC, Englund JA, Chu HY, Alter G
Cell Reports 2022
Correlates of protection against SARS-CoV-2 infection and COVID-19 disease.
Goldblatt D, Alter G, Crotty S, Plotkin SA
Immunological Reviews 2022
Fc-Dependent Immunomodulation Induced by Antiviral Therapeutic Antibodies: New Perspectives for Eliciting Protective Immune Responses.
Pelegrin M, Marsile-Medun S, Abba-Moussa D, Souchard M, Naranjo-Gomez M
2022
Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains.
Case JB, Mackin S, Errico JM, Chong Z, Madden EA, Whitener B, Guarino B, Schmid MA, Rosenthal K, Ren K, Dang HV, Snell G, Jung A, Droit L, Handley SA, Halfmann PJ, Kawaoka Y, Crowe JE Jr, Fremont DH, Virgin HW, Loo YM, Esser MT, Purcell LA, Corti D, Diamond MS
Nature Communications 2022
A Novel Neuraminidase Virus-Like Particle Vaccine Offers Protection Against Heterologous H3N2 Influenza Virus Infection in the Porcine Model.
Pliasas VC, Menne Z, Aida V, Yin JH, Naskou MC, Neasham PJ, North JF, Wilson D, Horzmann KA, Jacob J, Skountzou I, Kyriakis CS
Frontiers in immunology 2022
Progress towards the Development of a Universal Influenza Vaccine
Wang WC, Sayedahmed EE, Sambhara S, Mittal SK
Viruses 2022
Hemagglutinin stalk-binding antibodies enhance effectiveness of neuraminidase inhibitors against influenza via Fc-dependent effector functions
Zhang A, Chaudhari H, Agung Y, D\u2019Agostino MR, Ang JC, Tugg Y, Miller MS
Cell reports. Medicine 2022
Assessment of Fcγ receptor-dependent binding of influenza hemagglutinin vaccine-induced antibodies in a non-human primate model
Masuta Y, Takahama S, Nogimori T, Moriyama S, Takahashi Y, Yamamoto T
iScience 2022
Modulating cholesterol-rich lipid rafts to disrupt influenza A virus infection
Li YJ, Chen CY, Yang JH, Chiu YF
Frontiers in immunology 2022
Universal antibody targeting the highly conserved fusion peptide provides cross-protection in mice.
Muralidharan A, Gravel C, Harris G, Hashem AM, Zhang W, Safronetz D, Van Domselaar G, Krammer F, Sauve S, Rosu-Myles M, Wang L, Chen W, Li X
Human Vaccines & Immunotherapeutics 2022
A broadly protective human monoclonal antibody targeting the sialidase activity of influenza A and B virus neuraminidases.
Yasuhara A, Yamayoshi S, Kiso M, Sakai-Tagawa Y, Okuda M, Kawaoka Y
Nature Communications 2022
Cross-Reactive Fc-Fused Single-Domain Antibodies to Hemagglutinin Stem Region Protect Mice from Group 1 Influenza a Virus Infection
Voronina DV, Shcheblyakov DV, Favorskaya IA, Esmagambetov IB, Dzharullaeva AS, Tukhvatulin AI, Zubkova OV, Popova O, Kan VY, Bandelyuk AS, Shmarov MM, Logunov DY, Naroditskiy BS, Gintsburg AL
Viruses 2022
Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection
Zhang A, Stacey HD, D\u2019Agostino MR, Tugg Y, Marzok A, Miller MS
Nature reviews. Immunology 2022
Co-immunization with hemagglutinin stem immunogens elicits cross-group neutralizing antibodies and broad protection against influenza A viruses
Moin SM, Boyington JC, Boyoglu-Barnum S, Gillespie RA, Cerutti G, Cheung CS, Cagigi A, Gallagher JR, Brand J, Prabhakaran M, Tsybovsky Y, Stephens T, Fisher BE, Creanga A, Ataca S, Rawi R, Corbett KS, Crank MC, Karlsson Hedestam GB, Gorman J, McDermott AB, Harris AK, Zhou T, Kwong PD, Shapiro L, Mascola JR, Graham BS, Kanekiyo M
Immunity 2022
Longevity and Mechanism of Heterosubtypic Protection Induced by M2SR (M2-Deficient Single-Replication) Live Influenza Virus Vaccine in Mice
Sarawar S, Gabaglia CR, Sanchez A, Hatta Y, Dias P, Neumann G, Kawaoka Y, Bilsel P
Human vaccines 2022
Nucleoside-Modified mRNA-Based Influenza Vaccines Circumvent Problems Associated with H3N2 Vaccine Strain Egg Adaptation
Gouma S, Furey C, Santos JJ, Parkhouse K, Weirick M, Muramatsu H, Pardi N, Fan SH, Weissman D, Hensley SE
Journal of virology 2022
Antivirals Targeting the Neuraminidase
Gubareva L, Mohan T
Cold Spring Harbor Perspectives in Medicine 2022
Understanding Host Immunity and the Gut Microbiota Inspires the New Development of Vaccines and Adjuvants
K Yakabe, J Uchiyama, M Akiyama, YG Kim
Pharmaceutics 2021
Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses
LJ Kerstetter, S Buckley, CM Bliss, L Coughlan
Frontiers in immunology 2021
On the road to ending the COVID-19 pandemic: Are we there yet?
JB Case, ES Winkler, JM Errico, MS Diamond
Virology 2021
There Is Strength in Numbers: Quantitation of Fc Gamma Receptors on Murine Tissue-Resident Macrophages
C Vorsatz, N Friedrich, F Nimmerjahn, M Biburger
International journal of molecular sciences 2021
Isotype-Specific Fc Effector Functions Enhance Antibody-Mediated Rift Valley Fever Virus Protection In Vivo
HN Cartwright, DJ Barbeau, AK McElroy, RE Dutch
mSphere 2021
Neutrophils and Influenza: A Thin Line between Helpful and Harmful
ST George, J Lai, J Ma, HD Stacey, MS Miller, CE Mullarkey
Human vaccines 2021
Antibody Focusing to Conserved Sites of Vulnerability: The Immunological Pathways for ‘Universal’ Influenza Vaccines
M Sangesland, D Lingwood
Human vaccines 2021
The Next Generation of Influenza Vaccines: Towards a Universal Solution
CL McMillan, PR Young, D Watterson, KJ Chappell
Human vaccines 2021
B Cell Responses against Influenza Viruses: Short-Lived Humoral Immunity against a Life-Long Threat
JJ Guthmiller, HA Utset, PC Wilson
Viruses 2021
Synergistic effect of non-neutralizing antibodies and interferon-γ for cross-protection against influenza
M Shibuya, S Tamiya, A Kawai, T Hirai, M Cragg, Y Yoshioka
iScience 2021
Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection
BM Gunn, S Bai
Human Vaccines & Immunotherapeutics 2021
Broadly neutralizing antibodies target a haemagglutinin anchor epitope
J Guthmiller, J Han, H Utset, L Li, L Lan, C Henry, C Stamper, M McMahon, G ODell, M Fernández-Quintero, A Freyn, F Amanat, O Stovicek, L Gentles, S Richey, A de la Peña, V Rosado, H Dugan, N Zheng, M Tepora, D Bitar, S Changrob, S Strohmeier, M Huang, A García-Sastre, K Liedl, J Bloom, R Nachbagauer, P Palese, F Krammer, L Coughlan, A Ward, P Wilson
Nature 2021
Unique structural solution from a VH3-30 antibody targeting the hemagglutinin stem of influenza A viruses
WD Harshbarger, D Deming, GJ Lockbaum, N Attatippaholkun, M Kamkaew, S Hou, M Somasundaran, JP Wang, RW Finberg, QK Zhu, CA Schiffer, WA Marasco
Nature Communications 2021
Influenza hemagglutinin-specific IgA Fc-effector functionality is restricted to stalk epitopes
AW Freyn, J Han, JJ Guthmiller, MJ Bailey, K Neu, HL Turner, VC Rosado, V Chromikova, M Huang, S Strohmeier, ST Liu, V Simon, F Krammer, AB Ward, P Palese, PC Wilson, R Nachbagauer
Proceedings of the National Academy of Sciences 2021
Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection
CJ Batty, MT Heise, EM Bachelder, KM Ainslie
Advanced Drug Delivery Reviews 2021
Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions
AR Shiakolas, KJ Kramer, D Wrapp, SI Richardson, A Schäfer, S Wall, N Wang, K Janowska, KA Pilewski, R Venkat, R Parks, NP Manamela, N Raju, EF Fechter, CM Holt, N Suryadevara, RE Chen, DR Martinez, RS Nargi, RE Sutton, JE Ledgerwood, BS Graham, MS Diamond, BF Haynes, P Acharya, RH Carnahan, JE Crowe, RS Baric, L Morris, JS McLellan, IS Georgiev
Reproduction 2021
Broad Reactivity Single Domain Antibodies against Influenza Virus and Their Applications to Vaccine Potency Testing and Immunotherapy
AT Yep, Y Takeuchi, OG Engelhardt, SE Hufton
Biomolecules 2021
Development of a Macrophage-Based ADCC Assay
MB Uccellini, S Aslam, ST Liu, F Alam, A García-Sastre
Human vaccines 2021
Tackling COVID-19 with neutralizing monoclonal antibodies
D Corti, LA Purcell, G Snell, D Veesler
Cell 2021
Decay of Fc-dependent antibody functions after mild to moderate COVID-19
WS Lee, KJ Selva, SK Davis, BD Wines, A Reynaldi, R Esterbauer, HG Kelly, ER Haycroft, HX Tan, JA Juno, AK Wheatley, PM Hogarth, D Cromer, MP Davenport, AW Chung, SJ Kent
Reproduction 2021
Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection
ES Winkler, P Gilchuk, J Yu, AL Bailey, RE Chen, Z Chong, SJ Zost, H Jang, Y Huang, JD Allen, JB Case, RE Sutton, RH Carnahan, TL Darling, AC Boon, M Mack, RD Head, TM Ross, JE Crowe, MS Diamond
Cell 2021
A non-neutralizing antibody broadly protects against influenza virus infection by engaging effector cells
YA Ko, YH Yu, YF Wu, YC Tseng, CL Chen, KS Goh, HY Liao, TH Chen, TJ Cheng, AS Yang, CH Wong, C Ma, KI Lin, SL Klein
PLoS pathogens 2021
Immune Responses Elicited by Live Attenuated Influenza Vaccines as Correlates of Universal Protection against Influenza Viruses
YH Jang, BL Seong
Human vaccines 2021
Stabilized coronavirus spike stem elicits a broadly protective antibody
CL Hsieh, AP Werner, SR Leist, LJ Stevens, E Falconer, JA Goldsmith, CW Chou, OM Abiona, A West, K Westendorf, K Muthuraman, EJ Fritch, KH Dinnon, A Schäfer, MR Denison, JD Chappell, RS Baric, BS Graham, KS Corbett, JS McLellan
Cell Reports 2021
Requirement of Fc-Fc Gamma Receptor Interaction for Antibody-Based Protection against Emerging Virus Infections
SP Keeler, JM Fox
Viruses 2021
IgA potentiates NETosis in response to viral infection
HD Stacey, D Golubeva, A Posca, JC Ang, KE Novakowski, MA Zahoor, C Kaushic, E Cairns, DM Bowdish, CE Mullarkey, MS Miller
Proceedings of the National Academy of Sciences 2021
Mice with diverse microbial exposure histories as a model for preclinical vaccine testing
JK Fiege, KE Block, MJ Pierson, H Nanda, FK Shepherd, CK Mickelson, JM Stolley, WE Matchett, S Wijeyesinghe, DK Meyerholz, V Vezys, SS Shen, SE Hamilton, D Masopust, RA Langlois
Cell Host & Microbe 2021
Fc-Independent Protection from SARS-CoV-2 Infection by Recombinant Human Monoclonal Antibodies
T Noy-Porat, A Edri, R Alcalay, E Makdasi, D Gur, M Aftalion, Y Evgy, A Beth-Din, Y Levy, E Epstein, O Radinsky, A Zauberman, S Lazar, S Yitzhaki, H Marcus, A Porgador, R Rosenfeld, O Mazor
Antibodies 2021
Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant
Y Cheong, M Kim, J Ahn, H Oh, J Lim, W Chae, SW Yang, MS Kim, JE Yu, S Byun, YH Jang, BL Seong
Frontiers in immunology 2021
Matrix M Adjuvanted H5N1 Vaccine Elicits Broadly Neutralizing Antibodies and Neuraminidase Inhibiting Antibodies in Humans That Correlate With In Vivo Protection
F Zhou, L Hansen, G Pedersen, G Grødeland, R Cox
Frontiers in immunology 2021
Cross-reactive antibodies after SARS-CoV-2 infection and vaccination
M Grobben, K van der Straten, PJ Brouwer, M Brinkkemper, P Maisonnasse, N Dereuddre-Bosquet, B Appelman, AH Lavell, LA van Vught, JA Burger, M Poniman, M Oomen, D Eggink, TP Bijl, HD van Willigen, E Wynberg, BJ Verkaik, OJ Figaroa, PJ de Vries, TM Boertien, MK Bomers, JJ Sikkens, RL Grand, MD de Jong, M Prins, AW Chung, GJ de Bree, RW Sanders, MJ van Gils
eLife 2021
Fc-engineered antibody therapeutics with improved efficacy against COVID-19
Jeffrey Ravetch, Rachel Yamin, Andrew Jones, Hans-Heinrich Hoffmann, Kevin Kao, Rebecca Francis, Timothy Sheahan, Ralph Baric, Charles Rice, Stylianos Bournazos
Research square 2021
Influenza Neuraminidase Characteristics and Potential as a Vaccine Target
S Creytens, M Pascha, M Ballegeer, X Saelens, C de Haan
Frontiers in immunology 2021
Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters
W Su, S Sia, A Schmitz, T Bricker, T Starr, A Greaney, J Turner, B Mohammed, Z Liu, K Choy, T Darling, A Joshi, K Cheng, A Wong, H Harastani, J Nicholls, S Whelan, J Bloom, H Yen, A Ellebedy, A Boon, G Pier
mBio 2021
The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2)
N Beeraka, S Tulimilli, M Karnik, S Sadhu, R Pragada, G Aliev, S Madhunapantula, J Lu
BioMed Research International 2021
Intranasal vaccination with influenza HA/GO-PEI nanoparticles provides immune protection against homo- and heterologous strains
C Dong, Y Wang, G Gonzalez, Y Ma, Y Song, S Wang, S Kang, R Compans, B Wang
Proceedings of the National Academy of Sciences 2021
Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies
J Dufloo, L Grzelak, I Staropoli, Y Madec, L Tondeur, F Anna, S Pelleau, A Wiedemann, C Planchais, J Buchrieser, R Robinot, M Ungeheuer, H Mouquet, P Charneau, M White, Y Lévy, B Hoen, A Fontanet, O Schwartz, T Bruel
Cell reports. Medicine 2021
Strategies Targeting Hemagglutinin as a Universal Influenza Vaccine
B Bullard, E Weaver
Human vaccines 2021
Roles of the Fc Receptor γ-Chain in Inducing Protective Immune Responses after Heterologous Vaccination against Respiratory Syncytial Virus Infection
H Hwang, Y Lee, K Kim, H Seo, K Yang, H Cho, S Kang
Human vaccines 2021
Persistently high antibody responses after AS03-adjuvanted H1N1pdm09 vaccine: Dissecting the HA specific antibody response
A Madsen, Å Jul-Larsen, M Trieu, F Krammer, R Cox
npj Vaccines 2021
Development of mouse monoclonal antibody for detecting hemagglutinin of avian influenza A(H7N9) virus and preventing virus infection
Y Chiang, C Li, H Su, K Hsieh, C Weng, H Chen, S Chang
Applied Microbiology and Biotechnology 2021
Adjuvant Selection for Influenza and RSV Prefusion Subunit Vaccines
A Isaacs, Z Li, S Cheung, D Wijesundara, C McMillan, N Modhiran, P Young, C Ranasinghe, D Watterson, K Chappell
Human vaccines 2021
SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?
S Chakraborty, V Mallajosyula, C Tato, G Tan, T Wang
Advanced Drug Delivery Reviews 2021
An influenza HA stalk reactive polymeric IgA antibody exhibits anti-viral function regulated by binary interaction between HA and the antibody
K Sano, S Saito, T Suzuki, O Kotani, A Ainai, E van Riet, K Tabata, K Saito, Y Takahashi, M Yokoyama, H Sato, T Maruno, K Usami, S Uchiyama, K Ogawa-Goto, H Hasegawa, V Huber
PloS one 2021
Human anti-neuraminidase antibodies reduce airborne transmission of clinical influenza virus isolates in the guinea pig model
J Tan, G O'Dell, M Hernandez, E Sordillo, Z Kahn, D Kriti, H van Bakel, A Ellebedy, P Wilson, V Simon, F Krammer, M McMahon
Journal of virology 2021
Engineered Nanoparticulate Vaccines to Combat Recurring and Pandemic Influenza Threats
Dong C, Wang BZ
2021
Enhanced cross protection by hetero prime-boost vaccination with recombinant influenza viruses containing chimeric hemagglutinin-M2e epitopes
Park BR, Subbiah J, Kim KH, Kwon YM, Oh J, Kim MC, Shin CH, Seong BL, Kang SM
Virology 2021
Original Antigenic Sin: How Original? How Sinful?
Yewdell JW, Santos JJS
Cold Spring Harbor Perspectives in Medicine 2021
Preserved Omicron Spike specific antibody binding and Fc-recognition across COVID-19 vaccine platforms
Bartsch Y, Tong X, Kang J, José Avendaño M, Serrano EF, García-Salum T, Pardo-Roa C, Riquelme A, Medina RA, Alter G
2021
Influenza infected newborn and adult monkeys exhibit a strong primary antibody response to hemagglutinin stem
Elene A. Clemens, Davide Angeletti, Beth C. Holbrook, Masaru Kanekiyo, Matthew J. Jorgensen, Barney S. Graham, Jonathan W. Yewdell, Martha A. Alexander-Miller
JCI Insight 2020
The role of IgG Fc receptors in antibody-dependent enhancement
S Bournazos, A Gupta, JV Ravetch
Nature Reviews Immunology 2020
Airway Delivery of Anti-influenza Monoclonal Antibodies Results in Enhanced Antiviral Activities and Enables Broad-Coverage Combination Therapies
A Vigil, N Frias-Staheli, T Carabeo, M Wittekind, MT Heise
Journal of virology 2020
Recombinant Influenza Vaccines: Saviors to Overcome Immunodominance
NR Mathew, D Angeletti
Frontiers in immunology 2020
Establishment of a Pig Influenza Challenge Model for Evaluation of Monoclonal Antibody Delivery Platforms
A McNee, TR Smith, B Holzer, B Clark, E Bessell, G Guibinga, H Brown, K Schultheis, P Fisher, S Ramos, A Nunez, M Bernard, S Graham, V Martini, T Chrun, Y Xiao, JC Kash, JK Taubenberger, S Elliott, A Patel, P Beverley, P Rijal, DB Weiner, A Townsend, KE Broderick, E Tchilian
Journal of immunology (Baltimore, Md. : 1950) 2020
Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice
CM Bliss, AJ Parsons, R Nachbagauer, JR Hamilton, F Cappuccini, M Ulaszewska, JP Webber, A Clayton, AV Hill, L Coughlan
Molecular Therapy — Methods & Clinical Development 2020
Influenza A Virus Antibodies with Antibody-Dependent Cellular Cytotoxicity Function
R Gao, Z Sheng, CC Sreenivasan, D Wang, F Li
Viruses 2020
Adeno‐associated virus‐vectored influenza vaccine elicits neutralizing and Fcγ receptor‐activating antibodies
DE Demminger, L Walz, K Dietert, H Hoffmann, O Planz, AD Gruber, V Messling, T Wolff
EMBO Molecular Medicine 2020
The potential danger of suboptimal antibody responses in COVID-19
A Iwasaki, Y Yang
Nature Reviews Immunology 2020
The Transcription Factor T-bet Resolves Memory B Cell Subsets with Distinct Tissue Distributions and Antibody Specificities in Mice and Humans
JL Johnson, RL Rosenthal, JJ Knox, A Myles, MS Naradikian, J Madej, M Kostiv, AM Rosenfeld, W Meng, SR Christensen, SE Hensley, J Yewdell, DH Canaday, J Zhu, AB McDermott, Y Dori, M Itkin, EJ Wherry, N Pardi, D Weissman, A Naji, ET Prak, MR Betts, MP Cancro
Immunity 2020
Viruses to fight other viruses: the influenza vaccine case
JA Bengoechea
EMBO Molecular Medicine 2020
Influenza vaccination strategies targeting the hemagglutinin stem region
H Fukuyama, R Shinnakasu, T Kurosaki
Immunological Reviews 2020
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
J Hansen, A Baum, KE Pascal, V Russo, S Giordano, E Wloga, BO Fulton, Y Yan, K Koon, K Patel, KM Chung, A Hermann, E Ullman, J Cruz, A Rafique, T Huang, J Fairhurst, C Libertiny, M Malbec, W Lee, R Welsh, G Farr, S Pennington, D Deshpande, J Cheng, A Watty, P Bouffard, R Babb, N Levenkova, C Chen, B Zhang, AR Hernandez, K Saotome, Y Zhou, M Franklin, S Sivapalasingam, DC Lye, S Weston, J Logue, R Haupt, M Frieman, G Chen, W Olson, AJ Murphy, N Stahl, GD Yancopoulos, CA Kyratsous
Science 2020
Murine Cross-Reactive Nonneutralizing Polyclonal IgG1 Antibodies Induced by Influenza Vaccine Inhibit the Cross-Protective Effect of IgG2 against Heterologous Virus in Mice
M Shibuya, T Aoshi, E Kuroda, Y Yoshioka, S Schultz-Cherry
Journal of virology 2020
Protection From Influenza by Intramuscular Gene Vector Delivery of a Broadly Neutralizing Nanobody Does Not Depend on Antibody Dependent Cellular Cytotoxicity
JM Rosario, M Smith, K Zaki, P Risley, N Temperton, OG Engelhardt, M Collins, Y Takeuchi, SE Hufton
Frontiers in immunology 2020
The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19
AH Mansourabadi, M Sadeghalvad, HR Mohammadi-Motlagh, N Rezaei
Life Sciences 2020
Prospects and Challenges in the Development of Universal Influenza Vaccines
A Madsen, RJ Cox
Human vaccines 2020
Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection
S Bournazos, D Corti, HW Virgin, JV Ravetch
Nature 2020
Subdominance in Antibody Responses: Implications for Vaccine Development
G Lindahl
Microbiology and molecular biology reviews : MMBR 2020
Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19
K Karthik, TM Senthilkumar, S Udhayavel, GD Raj
Human Vaccines & Immunotherapeutics 2020
Antibody-dependent cell-mediated cytotoxicity antibody responses to inactivated and live-attenuated influenza vaccination in children during 2014–15
K Florek, J Mutschler, HQ McLean, JP King, B Flannery, EA Belongia, TC Friedrich
Vaccine 2020
A Vaccine Displaying a Trimeric Influenza-A HA Stem Protein on Capsid-Like Particles Elicits Potent and Long-Lasting Protection in Mice
S Thrane, KL Aves, IE Uddbäck, CM Janitzek, J Han, YR Yang, AB Ward, TG Theander, MA Nielsen, A Salanti, AR Thomsen, JP Christensen, AF Sander
Human vaccines 2020
Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
WS Lee, AK Wheatley, SJ Kent, BJ DeKosky
Nature Microbiology 2020
Augmented reality in scientific visualization and communications: a new dawn of looking at antibody interactions
K Chan, J Poh, W Wu, S Gan
2020
Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo
A Schäfer, F Muecksch, J Lorenzi, S Leist, M Cipolla, S Bournazos, F Schmidt, R Maison, A Gazumyan, D Martinez, R Baric, D Robbiani, T Hatziioannou, J Ravetch, P Bieniasz, R Bowen, M Nussenzweig, T Sheahan
Journal of Experimental Medicine 2020
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology
L Piccoli, Y Park, M Tortorici, N Czudnochowski, A Walls, M Beltramello, C Silacci-Fregni, D Pinto, L Rosen, J Bowen, O Acton, S Jaconi, B Guarino, A Minola, F Zatta, N Sprugasci, J Bassi, A Peter, A Marco, J Nix, F Mele, S Jovic, B Rodriguez, S Gupta, F Jin, G Piumatti, G Presti, A Pellanda, M Biggiogero, M Tarkowski, M Pizzuto, E Cameroni, C Havenar-Daughton, M Smithey, D Hong, V Lepori, E Albanese, A Ceschi, E Bernasconi, L Elzi, P Ferrari, C Garzoni, A Riva, G Snell, F Sallusto, K Fink, H Virgin, A Lanzavecchia, D Corti, D Veesler
Cell 2020
Chimeric hemagglutinin vaccine elicits broadly protective CD4 and CD8 T cell responses against multiple influenza strains and subtypes
Liao HY, Wang SC, Ko YA, Lin KI, Ma C, Cheng TJ, Wong CH
Proceedings of the National Academy of Sciences 2020
Characterization of Novel Cross-Reactive Influenza B Virus Hemagglutinin Head Specific Antibodies That Lack Hemagglutination Inhibition Activity.
Kirkpatrick E, Henry C, McMahon M, Jiang K, Strohmeier S, van Bakel H, Wilson PC, Krammer F
Journal of virology 2020
Engineered Recombinant Single Chain Variable Fragment of Monoclonal Antibody Provides Protection to Chickens Infected with H9N2 Avian Influenza.
Lukosaityte D, Sadeyen JR, Shrestha A, Sealy JE, Bhat S, Chang P, Digard P, Iqbal M
Human vaccines 2020
Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection in vivo.
Schäfer A, Muecksch F, Lorenzi JCC, Leist SR, Cipolla M, Bournazos S, Schmidt F, Gazumyan A, Baric RS, Robbiani DF, Hatziioannou T, Ravetch JV, Bieniasz PD, Nussenzweig MC, Sheahan TP
bioRxiv : the preprint server for biology 2020
Functional diversification of IgGs through Fc glycosylation
Taia Wang, Jeffrey Ravetch
Journal of Clinical Investigation 2019
Selective induction of antibody effector functional responses using MF59-adjuvanted vaccination
Carolyn M Boudreau, Wen-Han Yu, Todd J. Suscovich, H Keipp Talbot, Kathryn Edwards, Galit Alter
Journal of Clinical Investigation 2019
Exposure of an occluded hemagglutinin epitope drives selection of a class of cross-protective influenza antibodies
Y Adachi, K Tonouchi, A Nithichanon, M Kuraoka, A Watanabe, R Shinnakasu, H Asanuma, A Ainai, Y Ohmi, T Yamamoto, KJ Ishii, H Hasegawa, H Takeyama, G Lertmemongkolchai, T Kurosaki, M Ato, G Kelsoe, Y Takahashi
Nature Communications 2019
The Multifaceted B Cell Response to Influenza Virus
JH Lam, N Baumgarth
Journal of immunology (Baltimore, Md. : 1950) 2019
The Quest for a Truly Universal Influenza Vaccine
YH Jang, BL Seong
Frontiers in Cellular and Infection Microbiology 2019
Antiviral Functions of Monoclonal Antibodies against Chikungunya Virus
J Jin, G Simmons
Viruses 2019
T and B Cell Immune Responses to Influenza Viruses in Pigs
B Holzer, V Martini, M Edmans, E Tchilian
Frontiers in immunology 2019
A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface
S Bangaru, S Lang, M Schotsaert, HA Vanderven, X Zhu, N Kose, R Bombardi, JA Finn, SJ Kent, P Gilchuk, I Gilchuk, HL Turner, A García-Sastre, S Li, AB Ward, IA Wilson, JE Crowe
Cell 2019
Quantifying Antibody Responses Induced by Antigen-Agnostic Immunotherapies
JP van Vloten, EM Klafuric, K Karimi, G McFadden, JJ Petrik, SK Wootton, BW Bridle
Molecular Therapy — Methods & Clinical Development 2019
Antibody-Dependent Cellular Phagocytosis in Antiviral Immune Responses
MZ Tay, K Wiehe, J Pollara
Frontiers in immunology 2019
Extra-Neutralizing FcR-Mediated Antibody Functions for a Universal Influenza Vaccine
CM Boudreau, G Alter
Frontiers in immunology 2019
Understudied Factors Influencing Fc-Mediated Immune Responses against Viral Infections
SP Anand, A Finzi
Human vaccines 2019
Differential requirements for FcγR engagement by protective antibodies against Ebola virus
S Bournazos, DJ DiLillo, AJ Goff, PJ Glass, JV Ravetch
Proceedings of the National Academy of Sciences 2019
Influenza H7N9 Virus Neuraminidase-Specific Human Monoclonal Antibodies Inhibit Viral Egress and Protect from Lethal Influenza Infection in Mice
IM Gilchuk, S Bangaru, P Gilchuk, RP Irving, N Kose, RG Bombardi, NJ Thornburg, CB Creech, KM Edwards, S Li, HL Turner, W Yu, X Zhu, IA Wilson, AB Ward, JE Crowe
Cell Host & Microbe 2019
Outflanking immunodominance to target subdominant broadly neutralizing epitopes
D Angeletti, I Kosik, JJ Santos, WT Yewdell, CM Boudreau, VV Mallajosyula, MC Mankowski, M Chambers, M Prabhakaran, HD Hickman, AB McDermott, G Alter, J Chaudhuri, JW Yewdell
Proceedings of the National Academy of Sciences 2019
Influenza and Antibody-Dependent Cellular Cytotoxicity
TA Holle, MA Moody
Frontiers in immunology 2019
Broadly Inhibiting Antineuraminidase Monoclonal Antibodies Induced by Trivalent Influenza Vaccine and H7N9 Infection in Humans
P Rijal, BB Wang, TK Tan, L Schimanski, P Janesch, T Dong, JW McCauley, RS Daniels, AR Townsend, KY Huang, S Schultz-Cherry
Journal of virology 2019
Enhancing the cross protective efficacy of live attenuated influenza virus vaccine by supplemented vaccination with M2 ectodomain virus-like particles
YT Lee, KH Kim, EJ Ko, MC Kim, YN Lee, HS Hwang, Y Lee, YJ Jung, YJ Kim, J Santos, DR Perez, SM Kang
Virology 2019
The use of cell-mediated immunity for the evaluation of influenza vaccines: an upcoming necessity
E Gianchecchi, A Torelli, E Montomoli
Human Vaccines & Immunotherapeutics 2019
Cross-lineage protection by human antibodies binding the influenza B hemagglutinin
Y Liu, HX Tan, M Koutsakos, S Jegaskanda, R Esterbauer, D Tilmanis, M Aban, K Kedzierska, AC Hurt, SJ Kent, AK Wheatley
Nature Communications 2019
Neuraminidase inhibition contributes to influenza A virus neutralization by anti-hemagglutinin stem antibodies
I Kosik, D Angeletti, JS Gibbs, M Angel, K Takeda, M Kosikova, V Nair, HD Hickman, H Xie, CB Brooke, JW Yewdell
Journal of Experimental Medicine 2019
Characterization of Mouse Monoclonal Antibodies Against the HA of A(H7N9) Influenza Virus
M Ito, S Yamayoshi, K Murakami, K Saito, A Motojima, K Nakaishi, Y Kawaoka
Viruses 2019
Egg-based influenza split virus vaccine with monoglycosylation induces cross-strain protection against influenza virus infections
YC Tseng, CY Wu, ML Liu, TH Chen, WL Chiang, YH Yu, JT Jan, KI Lin, CH Wong, C Ma
Proceedings of the National Academy of Sciences 2019
The human antibody response to influenza A virus infection and vaccination
F Krammer
Nature Reviews Immunology 2019
Broad and Protective Influenza B Virus Neuraminidase Antibodies in Humans after Vaccination and their Clonal Persistence as Plasma Cells
MS Piepenbrink, A Nogales, M Basu, CF Fucile, JL Liesveld, MC Keefer, AF Rosenberg, L Martinez-Sobrido, JJ Kobie, A Moscona
mBio 2019
Influenza Hemagglutinin and Neuraminidase: Yin–Yang Proteins Coevolving to Thwart Immunity
I Kosik, JW Yewdell
Viruses 2019
“Breathing” Hemagglutinin Reveals Cryptic Epitopes for Universal Influenza Vaccine Design
Y Wu, GF Gao
Cell 2019
Universal Influenza Virus Vaccines That Target the Conserved Hemagglutinin Stalk and Conserved Sites in the Head Domain
F Krammer, P Palese
The Journal of Infectious Diseases 2019
Drugs for Influenza Treatment: Is There Significant News?
N Principi, B Camilloni, A Alunno, I Polinori, A Argentiero, S Esposito
Frontiers in Medicine 2019
Antibodies to a Conserved Influenza Head Interface Epitope Protect by an IgG Subtype-Dependent Mechanism
A Watanabe, KR McCarthy, M Kuraoka, AG Schmidt, Y Adachi, T Onodera, K Tonouchi, TM Caradonna, G Bajic, S Song, CE McGee, GD Sempowski, F Feng, P Urick, TB Kepler, Y Takahashi, SC Harrison, G Kelsoe
Cell 2019
Protective Antibodies Against Influenza Proteins
HO Padilla-Quirarte, DV Lopez-Guerrero, L Gutierrez-Xicotencatl, F Esquivel-Guadarrama
Frontiers in immunology 2019
Targeting Conventional Dendritic Cells to Fine-Tune Antibody Responses
DY Tesfaye, A Gudjonsson, B Bogen, E Fossum
Frontiers in immunology 2019
Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase
F Broecker, A Zheng, N Suntronwong, W Sun, MJ Bailey, F Krammer, P Palese, TS Dermody
Journal of virology 2019
A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation
S Fischinger, JK Fallon, AR Michell, T Broge, TJ Suscovich, H Streeck, G Alter
Journal of Immunological Methods 2019
Germline-Encoded Affinity for Cognate Antigen Enables Vaccine Amplification of a Human Broadly Neutralizing Response against Influenza Virus
M Sangesland, L Ronsard, SW Kazer, J Bals, S Boyoglu-Barnum, AS Yousif, R Barnes, J Feldman, M Quirindongo-Crespo, PM McTamney, D Rohrer, N Lonberg, B Chackerian, BS Graham, M Kanekiyo, AK Shalek, D Lingwood
Immunity 2019
Fcγ Receptors Contribute to the Antiviral Properties of Influenza Virus Neuraminidase-Specific Antibodies
ER Job, T Ysenbaert, A Smet, AV Hecke, L Meuris, H Kleanthous, X Saelens, TU Vogel, P Palese
mBio 2019
Antibody-Dependent Natural Killer Cell Activation After Ebola Vaccination
HR Wagstaffe, EA Clutterbuck, V Bockstal, JN Stoop, K Luhn, M Douoguih, G Shukarev, MD Snape, AJ Pollard, EM Riley, MR Goodier
The Journal of Infectious Diseases 2019
Neuraminidase expressing virus-like particle vaccine provides effective cross protection against influenza virus
KH Kim, YT Lee, S Park, YJ Jung, Y Lee, EJ Ko, YJ Kim, X Li, SM Kang
Virology 2019
Non-neutralizing Antibodies Directed at Conservative Influenza Antigens
Sedova ES, Scherbinin DN, Lysenko AA, Alekseeva SV, Artemova EA, Shmarov MM
Acta Naturae 2019
Immunity to Influenza Infection in Humans
DJ Topham, ML DeDiego, A Nogales, MY Sangster, A Sant
Cold Spring Harbor Perspectives in Medicine 2019
Integrative Physiology of Pneumonia
LJ Quinton, AJ Walkey, JP Mizgerd
Physiological reviews 2018
Universal Influenza Vaccines: Progress in Achieving Broad Cross-Protection In Vivo
SL Epstein
American Journal of Epidemiology 2018
Treating Influenza Infection, From Now and Into the Future
S Davidson
Frontiers in immunology 2018
The Unexpected Impact of Vaccines on Secondary Bacterial Infections Following Influenza
AM Smith, VC Huber
Viral Immunology 2018
Combination of M2e peptide with stalk HA epitopes of influenza A virus enhances protective properties of recombinant vaccine
LM Tsybalova, LA Stepanova, MA Shuklina, ES Mardanova, RY Kotlyarov, MV Potapchuk, SA Petrov, EA Blokhina, NV Ravin, S Pöhlmann
PloS one 2018
Passive immunization with influenza haemagglutinin specific monoclonal antibodies
R Rudraraju, K Subbarao
Human Vaccines & Immunotherapeutics 2018
Mini-hemagglutinin vaccination induces cross-reactive antibodies in pre-exposed NHP that protect mice against lethal influenza challenge
JE van der Lubbe, J Huizingh, JW Verspuij, L Tettero, SP Schmit-Tillemans, P Mooij, D Mortier, G Koopman, WM Bogers, L Dekking, W Meijberg, T Kwaks, B Brandenburg, JT Tolboom, H Schuitemaker, R Roozendaal, H Kuipers, RC Zahn
npj Vaccines 2018
Human protective monoclonal antibodies against the HA stem of group 2 HAs derived from an H3N2 virus-infected human
S Yamayoshi, M Ito, R Uraki, T Sasaki, K Ikuta, Y Kawaoka
Journal of Infection 2018
Influenza
F Krammer, GJ Smith, RA Fouchier, M Peiris, K Kedzierska, PC Doherty, P Palese, ML Shaw, J Treanor, RG Webster, A García-Sastre
Nature Reviews Disease Primers 2018
Distinct and complementary roles of CD4 T cells in protective immunity to influenza virus
AJ Sant, KA Richards, J Nayak
Current Opinion in Immunology 2018
Comprehensive analysis of N -glycans in IgG purified from ferrets with or without influenza A virus infection
G Zou, M Kosikova, SR Kim, S Kotian, WW Wu, R Shen, DN Powers, C Agarabi, H Xie, T Ju
The Journal of biological chemistry 2018
Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies
YQ Chen, TJ Wohlbold, NY Zheng, M Huang, Y Huang, KE Neu, J Lee, H Wan, KT Rojas, E Kirkpatrick, C Henry, AK Palm, CT Stamper, LY Lan, DJ Topham, J Treanor, J Wrammert, R Ahmed, MC Eichelberger, G Georgiou, F Krammer, PC Wilson
Cell 2018
A Highly Potent and Broadly Neutralizing H1 Influenza-Specific Human Monoclonal Antibody
A Nogales, MS Piepenbrink, J Wang, S Ortega, M Basu, CF Fucile, JJ Treanor, AF Rosenberg, MS Zand, MC Keefer, L Martinez-Sobrido, JJ Kobie
Scientific Reports 2018
Immunological responses to influenza vaccination: lessons for improving vaccine efficacy
, S Bournazos, JV Ravetch
Current Opinion in Immunology 2018
How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin
MB Doud, JM Lee, JD Bloom
Nature Communications 2018
The Potential Role of Fc-Receptor Functions in the Development of a Universal Influenza Vaccine
S Jegaskanda
Human vaccines 2018
Antibody Immunodominance: The Key to Understanding Influenza Virus Antigenic Drift
MO Altman, D Angeletti, JW Yewdell
Viral Immunology 2018
A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus
BM Gunn, WH Yu, MM Karim, JM Brannan, AS Herbert, AZ Wec, PJ Halfmann, ML Fusco, SL Schendel, K Gangavarapu, T Krause, X Qiu, S He, J Das, TJ Suscovich, J Lai, K Chandran, L Zeitlin, JE Crowe, D Lauffenburger, Y Kawaoka, GP Kobinger, KG Andersen, JM Dye, EO Saphire, G Alter
Cell Host & Microbe 2018
Therapeutic Administration of Broadly Neutralizing FI6 Antibody Reveals Lack of Interaction Between Human IgG1 and Pig Fc Receptors
SB Morgan, B Holzer, JD Hemmink, FJ Salguero, JC Schwartz, G Agatic, E Cameroni, B Guarino, E Porter, P Rijal, A Townsend, B Charleston, D Corti, E Tchilian
Frontiers in immunology 2018
Anti-influenza Hyperimmune Immunoglobulin Enhances Fc-functional Antibody Immunity during Human Influenza Infection
HA Vanderven, K Wragg, F Ana-Sosa-Batiz, AB Kristensen, S Jegaskanda, AK Wheatley, D Wentworth, BD Wines, PM Hogarth, S Rockman, SJ Kent
The Journal of Infectious Diseases 2018
Characterization of Hemagglutinin Antigens on Influenza Virus and within Vaccines Using Electron Microscopy
J Gallagher, D McCraw, U Torian, N Gulati, M Myers, M Conlon, A Harris
Human vaccines 2018
Asymmetric antiviral effects of ebolavirus antibodies targeting glycoprotein stem and glycan cap
PA Ilinykh, RI Santos, BM Gunn, NA Kuzmina, X Shen, K Huang, P Gilchuk, AI Flyak, P Younan, G Alter, JE Crowe, A Bukreyev, JH Kuhn
PLoS pathogens 2018
Roles of Fc Domain and Exudation in L2 Antibody-Mediated Protection against Human Papillomavirus
JW Wang, WH Wu, TC Huang, M Wong, K Kwak, K Ozato, CF Hung, RB Roden, L Banks
Journal of virology 2018
Cross-reactive mouse monoclonal antibodies raised against the hemagglutinin of A/Shanghai/1/2013 (H7N9) protect against novel H7 virus isolates in the mouse model
D Stadlbauer, F Amanat, S Strohmeier, R Nachbagauer, F Krammer
Emerging Microbes & Infections 2018
Development of a high-throughput assay to detect antibody inhibition of low pH induced conformational changes of influenza virus hemagglutinin
JF Trost, EH LeMasters, F Liu, P Carney, X Lu, K Sugawara, S Hongo, J Stevens, DA Steinhauer, T Tumpey, JM Katz, MZ Levine, ZN Li, F Krammer
PloS one 2018
The Role of Fc Gamma Receptors in Broad Protection against Influenza Viruses
N Thulin, T Wang
Human vaccines 2018
Heterosubtypic influenza protection elicited by double-layered polypeptide nanoparticles in mice
L Deng, TZ Chang, Y Wang, S Li, S Wang, S Matsuyama, G Yu, RW Compans, JD Li, MR Prausnitz, JA Champion, BZ Wang
Proceedings of the National Academy of Sciences 2018
Double-layered protein nanoparticles induce broad protection against divergent influenza A viruses
L Deng, T Mohan, TZ Chang, GX Gonzalez, Y Wang, YM Kwon, SM Kang, RW Compans, JA Champion, BZ Wang
Nature Communications 2018
Avian Influenza A Virus Pandemic Preparedness and Vaccine Development
R de Vries, S Herfst, M Richard
Human vaccines 2018
Comparison of Adjuvanted-Whole Inactivated Virus and Live-Attenuated Virus Vaccines against Challenge with Contemporary, Antigenically Distinct H3N2 Influenza A Viruses
EJ Abente, DS Rajao, J Santos, BS Kaplan, TL Nicholson, SL Brockmeier, PC Gauger, DR Perez, AL Vincent, S Schultz-Cherry
Journal of virology 2018
A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies
MJ Bailey, F Broecker, PE Leon, GS Tan
Journal of visualized experiments : JoVE 2018
Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model
MJ Bailey, J Duehr, H Dulin, F Broecker, JA Brown, FO Arumemi, MC González, VH Leyva-Grado, MJ Evans, V Simon, JK Lim, F Krammer, R Hai, P Palese, GS Tan
Nature Communications 2018
A unique nanoparticulate TLR9 agonist enables a HA split vaccine to confer FcγR-mediated protection against heterologous lethal influenza virus infection
T Yamamoto, Y Masuta, M Momota, M Kanekiyo, T Kanuma, S Takahama, E Moriishi, Y Yasutomi, T Saito, BS Graham, Y Takahashi, KJ Ishii
International Immunology 2018
Antibody Responses toward the Major Antigenic Sites of Influenza B Virus Hemagglutinin in Mice, Ferrets, and Humans
W Sun, DS Kang, A Zheng, ST Liu, F Broecker, V Simon, F Krammer, P Palese, TS Dermody
Journal of virology 2018
Broadened immunity against influenza by vaccination with computationally designed influenza virus N1 neuraminidase constructs
ER Job, T Ysenbaert, A Smet, I Christopoulou, T Strugnell, EO Oloo, RP Oomen, H Kleanthous, TU Vogel, X Saelens
npj Vaccines 2018
Influenza Virus Infection Enhances Antibody-Mediated NK Cell Functions via Type I Interferon-Dependent Pathways
S Jegaskanda, HA Vanderven, HX Tan, S Alcantara, KM Wragg, MS Parsons, AW Chung, JA Juno, SJ Kent, S Schultz-Cherry
Journal of virology 2018
Fc functional antibodies during severe human H7N9 and seasonal influenza
Hillary Vanderven, Lu Liu, Fernanda Ana-Sosa-Batiz, Thi HO Nguyen, yanmin wan, Bruce Wines, Mark Hogarth, Danielle Tilmanis, Arnold Reynaldi, Matthew Parsons, Aaron C. Hurt, Miles Davenport, Tom Kotsimbos, Allen Cheng, Katherine Kedzierska, xiaoyan zhang, Jianqing Xu, Stephen Kent
JCI Insight 2017
Beyond Viral Neutralization
GK Lewis, M Pazgier, DT Evans, G Ferrari, S Bournazos, MS Parsons, NF Bernard, A Finzi
AIDS Research and Human Retroviruses 2017
Signaling by Antibodies: Recent Progress
S Bournazos, TT Wang, R Dahan, J Maamary, JV Ravetch
Annual Review of Immunology 2017
Hierarchical and Redundant Roles of Activating FcγRs in Protection against Influenza Disease by M2e-Specific IgG1 and IgG2a Antibodies
SV Hoecke, K Ehrhardt, A Kolpe, KE Bakkouri, L Deng, H Grootaert, S Schoonooghe, A Smet, M Bentahir, K Roose, M Schotsaert, B Schepens, N Callewaert, F Nimmerjahn, P Staeheli, H Hengel, X Saelens, S Schultz-Cherry
Journal of virology 2017
A Broadly Reactive Human Anti-hemagglutinin Stem Monoclonal Antibody That Inhibits Influenza A Virus Particle Release
S Yamayoshi, R Uraki, M Ito, M Kiso, S Nakatsu, A Yasuhara, K Oishi, T Sasaki, K Ikuta, Y Kawaoka
EBioMedicine 2017
Intravenous Immunoglobulin Protects Against Severe Pandemic Influenza Infection
S Rockman, S Lowther, S Camuglia, K Vandenberg, S Taylor, L Fabri, S Miescher, M Pearse, D Middleton, SJ Kent, D Maher
EBioMedicine 2017
In Vitro Neutralization Is Not Predictive of Prophylactic Efficacy of Broadly Neutralizing Monoclonal Antibodies CR6261 and CR9114 against Lethal H2 Influenza Virus Challenge in Mice
TC Sutton, EW Lamirande, KW Bock, IN Moore, W Koudstaal, M Rehman, GJ Weverling, J Goudsmit, K Subbarao, A García-Sastre
Journal of virology 2017
Protective efficacy of influenza group 2 hemagglutinin stem-fragment immunogen vaccines
TC Sutton, S Chakraborty, VV Mallajosyula, EW Lamirande, K Ganti, KW Bock, IN Moore, R Varadarajan, K Subbarao
npj Vaccines 2017
Structural Insight into a Human Neutralizing Antibody against Influenza Virus H7N9
C Chen, L Liu, Y Xiao, S Cui, J Wang, Q Jin, RM Sandri-Goldin
Journal of virology 2017
IL-6 Production by TLR-Activated APC Broadly Enhances Aged Cognate CD4 Helper and B Cell Antibody Responses In Vivo
V Brahmakshatriya, Y Kuang, P Devarajan, J Xia, W Zhang, AM Vong, SL Swain
Journal of immunology (Baltimore, Md. : 1950) 2017
The establishment of surrogates and correlates of protection: Useful tools for the licensure of effective influenza vaccines?
BJ Ward, S Pillet, N Charland, S Trepanier, J Couillard, N Landry
Human Vaccines & Immunotherapeutics 2017
Pandemic 2009 H1N1 Influenza Venus reporter virus reveals broad diversity of MHC class II-positive antigen-bearing cells following infection in vivo
A DiPiazza, A Nogales, N Poulton, PC Wilson, L Martínez-Sobrido, AJ Sant
Scientific Reports 2017
Sudan ebolavirus long recovered survivors produce GP-specific Abs that are of the IgG1 subclass and preferentially bind FcγRI
O Radinsky, A Edri, M Brusilovsky, S Fedida-Metula, A Sobarzo, O Gershoni-Yahalom, J Lutwama, J Dye, L Lobel, A Porgador
Scientific Reports 2017
A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action
N Chai, LR Swem, S Park, G Nakamura, N Chiang, A Estevez, R Fong, L Kamen, E Kho, M Reichelt, Z Lin, H Chiu, E Skippington, Z Modrusan, J Stinson, M Xu, P Lupardus, C Ciferri, MW Tan
Nature Communications 2017
From Original Antigenic Sin to the Universal Influenza Virus Vaccine
C Henry, AK Palm, F Krammer, PC Wilson
Trends in Immunology 2017
A Potent Germline-like Human Monoclonal Antibody Targets a pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin
F Yu, H Song, Y Wu, SY Chang, L Wang, W Li, B Hong, S Xia, C Wang, S Khurana, Y Feng, Y Wang, Z Sun, B He, D Hou, J Manischewitz, LR King, Y Song, JY Min, H Golding, X Ji, L Lu, S Jiang, DS Dimitrov, T Ying
Cell Host & Microbe 2017
Non-Neutralizing Antibodies Directed against HIV and Their Functions
LM Mayr, B Su, C Moog
Frontiers in immunology 2017
Immune history and influenza virus susceptibility
S Cobey, SE Hensley
Current Opinion in Virology 2017
Conserved epitope on influenza-virus hemagglutinin head defined by a vaccine-induced antibody
DD Raymond, G Bajic, J Ferdman, P Suphaphiphat, EC Settembre, MA Moody, AG Schmidt, SC Harrison
Proceedings of the National Academy of Sciences 2017
Is It Possible to Develop a “Universal” Influenza Virus Vaccine?: Outflanking Antibody Immunodominance on the Road to Universal Influenza Vaccination
D Angeletti, JW Yewdell
Cold Spring Harbor perspectives in biology 2017
Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins
R Nachbagauer, A Choi, A Hirsh, I Margine, S Iida, A Barrera, M Ferres, RA Albrecht, A García-Sastre, NM Bouvier, K Ito, RA Medina, P Palese, F Krammer
Nature Immunology 2017
Modulating IgG effector function by Fc glycan engineering
T Li, DJ DiLillo, S Bournazos, JP Giddens, JV Ravetch, LX Wang
Proceedings of the National Academy of Sciences 2017
Fc or not Fc; that is the question: Antibody Fc-receptor interactions are key to universal influenza vaccine design
S Jegaskanda, HA Vanderven, AK Wheatley, SJ Kent
Human Vaccines & Immunotherapeutics 2017
Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice
W He, CJ Chen, CE Mullarkey, JR Hamilton, CK Wong, PE Leon, MB Uccellini, V Chromikova, C Henry, KW Hoffman, JK Lim, PC Wilson, MS Miller, F Krammer, P Palese, GS Tan
Nature Communications 2017
Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes
TJ Wohlbold, KA Podolsky, V Chromikova, E Kirkpatrick, V Falconieri, P Meade, F Amanat, J Tan, BR tenOever, GS Tan, S Subramaniam, P Palese, F Krammer
Nature Microbiology 2017
A modified vaccinia Ankara vaccine vector expressing a mosaic H5 hemagglutinin reduces viral shedding in rhesus macaques
NW Florek, A Kamlangdee, JP Mutschler, B Kingstad-Bakke, N Schultz-Darken, KW Broman, JE Osorio, TC Friedrich, S Pöhlmann
PloS one 2017
Conformational modulation of influenza virus hemagglutinin: characterization and in vivo efficacy of monomeric form
JH Seok, J Kim, DB Lee, KJ Cho, JH Lee, G Bae, MS Chung, KH Kim
Scientific Reports 2017
An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody protects mice from morbidity without interfering with the development of protective immunity to subsequent homologous challenge
JR Wilson, JA Belser, J DaSilva, Z Guo, X Sun, S Gansebom, Y Bai, TJ Stark, J Chang, P Carney, MZ Levine, J Barnes, J Stevens, TR Maines, TM Tumpey, IA York
Virology 2017
Increasing the breadth and potency of response to the seasonal influenza virus vaccine by immune complex immunization
J Maamary, TT Wang, GS Tan, P Palese, JV Ravetch
Proceedings of the National Academy of Sciences 2017
In Vivo Production of Monoclonal Antibodies by Gene Transfer via Electroporation Protects against Lethal Influenza and Ebola Infections
CD Andrews, Y Luo, M Sun, J Yu, AJ Goff, PJ Glass, NN Padte, Y Huang, DD Ho
Molecular Therapy - Methods & Clinical Development 2017
Divergent Requirement of Fc-Fcγ Receptor Interactions for In Vivo Protection against Influenza Viruses by Two Pan-H5 Hemagglutinin Antibodies
S Wang, H Ren, W Jiang, H Chen, H Hu, Z Chen, P Zhou, S Perlman
Journal of virology 2017
The evolution of seasonal influenza viruses
VN Petrova, CA Russell
Nature Reviews Microbiology 2017
Primary Human Influenza B Virus Infection Induces Cross-Lineage Hemagglutinin Stalk–Specific Antibodies Mediating Antibody-Dependent Cellular Cytoxicity
RD de Vries, NJ Nieuwkoop, FR van der Klis, MP Koopmans, F Krammer, GF Rimmelzwaan
The Journal of Infectious Diseases 2017
Antibodies directed towards neuraminidase N1 control disease in a mouse model of influenza
ER Job, M Schotsaert, LI Ibañez, A Smet, T Ysenbaert, K Roose, M Dai, CA de Haan, H Kleanthous, TU Vogel, X Saelens
Journal of virology 2017
Tackling influenza with broadly neutralizing antibodies
Corti D, Cameroni E, Guarino B, Kallewaard NL, Zhu Q, Lanzavecchia A
Current Opinion in Virology 2017
Non-neutralizing antibodies induced by seasonal influenza vaccine prevent, not exacerbate A(H1N1)pdm09 disease
JH Kim, AJ Reber, A Kumar, P Ramos, G Sica, N Music, Z Guo, M Mishina, J Stevens, IA York, J Jacob, S Sambhara
Scientific Reports 2016
A Structural and Mathematical Modeling Analysis of the Likelihood of Antibody-Dependent Enhancement in Influenza
B Ramakrishnan, K Viswanathan, K Tharakaraman, V Dančík, R Raman, GJ Babcock, Z Shriver, R Sasisekharan
Trends in Microbiology 2016
Modulating Antibody Functionality in Infectious Disease and Vaccination
BM Gunn, G Alter
Trends in Molecular Medicine 2016
Immunoglobulin Glycosylation Effects in Allergy and Immunity
A Epp, KC Sullivan, AB Herr, RT Strait
Current Allergy and Asthma Reports 2016
Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes
NL Kallewaard, D Corti, PJ Collins, U Neu, JM McAuliffe, E Benjamin, L Wachter-Rosati, FJ Palmer-Hill, AQ Yuan, PA Walker, MK Vorlaender, S Bianchi, B Guarino, A De Marco, F Vanzetta, G Agatic, M Foglierini, D Pinna, B Fernandez-Rodriguez, A Fruehwirth, C Silacci, RW Ogrodowicz, SR Martin, F Sallusto, JA Suzich, A Lanzavecchia, Q Zhu, SJ Gamblin, JJ Skehel
Cell 2016
Commentary on ‘Dissecting the hemagglutinin head and stalk specific IgG antibody response in healthcare workers following pandemic H1N1 vaccination’
TM Ross
npj Vaccines 2016
Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Induce Potent Phagocytosis of Immune Complexes by Neutrophils in an Fc-Dependent Manner
CE Mullarkey, MJ Bailey, DA Golubeva, GS Tan, R Nachbagauer, W He, KE Novakowski, DM Bowdish, MS Miller, P Palese
mBio 2016
Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact
PE Leon, W He, CE Mullarkey, MJ Bailey, MS Miller, F Krammer, P Palese, GS Tan
Proceedings of the National Academy of Sciences 2016
Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection
CJ Dunand, PE Leon, M Huang, A Choi, V Chromikova, IY Ho, GS Tan, J Cruz, A Hirsh, NY Zheng, CE Mullarkey, FA Ennis, M Terajima, JJ Treanor, DJ Topham, K Subbarao, P Palese, F Krammer, PC Wilson
Cell Host & Microbe 2016
HA Antibody-Mediated FcγRIIIa Activity Is Both Dependent on FcR Engagement and Interactions between HA and Sialic Acids
F Cox, T Kwaks, B Brandenburg, MH Koldijk, V Klaren, B Smal, HJ Korse, E Geelen, L Tettero, D Zuijdgeest, EJ Stoop, E Saeland, R Vogels, RH Friesen, W Koudstaal, J Goudsmit
Frontiers in immunology 2016
Generation and Protective Ability of Influenza Virus–Specific Antibody-Dependent Cellular Cytotoxicity in Humans Elicited by Vaccination, Natural Infection, and Experimental Challenge
S Jegaskanda, C Luke, HD Hickman, MY Sangster, WF Wieland-Alter, JM McBride, JW Yewdell, PF Wright, J Treanor, CM Rosenberger, K Subbarao
The Journal of Infectious Diseases 2016
Unmasking Stem-Specific Neutralizing Epitopes by Abolishing N-Linked Glycosylation Sites of Influenza Virus Hemagglutinin Proteins for Vaccine Design
WC Liu, JT Jan, YJ Huang, TH Chen, SC Wu, S Perlman
Journal of virology 2016
Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination
J Lee, DR Boutz, V Chromikova, MG Joyce, C Vollmers, K Leung, AP Horton, BJ DeKosky, CH Lee, JJ Lavinder, EM Murrin, C Chrysostomou, KH Hoi, Y Tsybovsky, PV Thomas, A Druz, B Zhang, Y Zhang, L Wang, WP Kong, D Park, LI Popova, CL Dekker, MM Davis, CE Carter, TM Ross, AD Ellington, PC Wilson, EM Marcotte, JR Mascola, GC Ippolito, F Krammer, SR Quake, PD Kwong, G Georgiou
Nature Medicine 2016
Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus
W He, GS Tan, CE Mullarkey, AJ Lee, MM Lam, F Krammer, C Henry, PC Wilson, AA Ashkar, P Palese, MS Miller
Proceedings of the National Academy of Sciences 2016
Human seasonal influenza A viruses induce H7N9-cross-reactive antibody-dependent cellular cytotoxicity (ADCC) antibodies that are directed towards the nucleoprotein
S Jegaskanda, MD Co, J Cruz, K Subbarao, FA Ennis, M Terajima
The Journal of Infectious Diseases 2016
The Role and Function of Fcγ Receptors on Myeloid Cells.
Bournazos S, Wang TT, Ravetch JV
Microbiology spectrum 2016

← Previous 1 2 3 … 11 12 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 3 X users
Referenced in 18 patents
231 readers on Mendeley
See more details